Eventide Gilead Fund Institutional Class
ETILX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 4221 North 203rd Street, Suite 100 Elkhorn NE United States of America 68022-3474
- IPO Date
- Feb 2, 2010
- CIK
- 0001355064
- Website
- eventideinvestments.com
- Similar Companies
- Business
- Eventide Gilead Fund Institutional Class (ETILX) is a diversified equity mutual fund managed by Eventide Asset Management LLC that seeks long-term capital appreciation by investing primarily in a broad range of equity securities, with historical emphases on small- and mid-cap growth stocks in the health care and information technology sectors; it employs a thematic approach targeting companies positioned for long-term secular trends while applying proprietary Business 360° criteria to select firms demonstrating ethical practices that serve customers, employees, suppliers, communities, the environment, and society broadly; the portfolio typically holds 60 to 80 positions across sectors including technology (approximately 31%), healthcare (27%), industrials (18%), and consumer cyclical (10%), with top holdings such as Xometry Inc., Guardant Health Inc., Mirum Pharmaceuticals Inc., Toast Inc., and Trane Technologies plc as of late 2025. ETILX operates within the U.S. mid-cap growth category, available to institutional investors with a minimum initial investment of $100,000 and an expense ratio of 1.16%; it features annual distributions and low market correlation through high internal diversification. Launched on February 2, 2010, with Eventide Asset Management headquartered in Boston, Massachusetts, the fund is led by Co-Chief Investment Officer and Senior Portfolio Manager Finny Kuruvilla, MD, PhD, a founding member of Eventide with expertise in healthcare investing. In recent developments, Eventide Asset Management, the fund's adviser, launched three new systematic ETFs—Eventide U.S. Large Cap ETF (ESLG), Eventide Large Cap Value ETF (ESLV), and Eventide Small Cap ETF (ESSC)—in September 2025 to broaden its offerings with faith-based, passive-active strategies screened via Business 360° methodology; the firm also expanded client types to include these ETFs and introduced systematic investment strategies alongside new analytical tools as of March 2025, while filing for an international ETF (ESIM). In 2024, Eventide launched a private healthcare fund with performance fees, further diversifying its product suite beyond mutual funds like ETILX into ETFs, separately managed accounts, model portfolios, and Eventide Ventures for private healthcare opportunities; portfolio adjustments included increased stakes in biopharma names like Royalty Pharma plc in Q2 2025. The fund remains domiciled in the United States, with geographic exposure primarily to U.S. equities (81%) supplemented by non-U.S. stocks (14%), targeting investors seeking values-aligned growth with total net assets exceeding $2.5 billion as of late 2025.